Gepotidacin for UTIs: Can It Expand Antibiotic Options?

Why do pandemic resistance findings matter for UTI treatment?

CDC reports that hospital-onset resistant infections and associated deaths increased by at least 15% between 2019 and 2020 across seven pathogens. Its account describes disrupted infection prevention, strained laboratories and antibiotic prescribing for patients with a viral illness. These are historical findings, rather than newly measured October figures, and they do not establish that COVID-19 caused resistance in an individual patient's UTI. [CDC pandemic resistance assessment](https://www.cdc.gov/antimicrobial-resistance/data-research/threats/covid-19.html)

One subsequent treatment advance was the FDA's March 25, 2025 approval of gepotidacin, marketed as Blujepa, for uncomplicated UTIs caused by specified susceptible bacteria. The UTI indication covers female patients aged 12 or older who weigh at least 40 kilograms. Its relevance to the resistance challenge is an additional oral option for eligible patients; the approval does not establish effectiveness against every resistant urinary infection. [FDA approval and trial overview](https://www.fda.gov/drugs/drug-trials-snapshots/drug-trials-snapshots-blujepa)

How effective was gepotidacin compared with nitrofurantoin?

The randomized, blinded EAGLE-2 and EAGLE-3 trials compared five-day oral courses. In the primary analyses published in The Lancet in 2024, therapeutic success occurred in 50.6% versus 47.0% of evaluated participants in EAGLE-2, and 58.5% versus 43.6% in EAGLE-3, for gepotidacin and nitrofurantoin respectively. Success required both complete symptom resolution and a qualifying reduction in bacteria at follow-up, without additional antibiotics for the infection. These percentages therefore describe a stricter outcome than symptom improvement alone. [Published EAGLE trial results](https://pubmed.ncbi.nlm.nih.gov/38342126/)

A crucial limitation is that the primary efficacy population had bacteria susceptible to nitrofurantoin. The results should not be interpreted as proof that gepotidacin cures all infections resistant to standard antibiotics. The studies received funding from GSK and the Biomedical Advanced Research and Development Authority. Their findings support an additional treatment option, while leaving antibiotic selection dependent on the infection, susceptibility information and patient characteristics. [Trial methods, interpretation and funding](https://pubmed.ncbi.nlm.nih.gov/38342126/)

How does gepotidacin work, and what limits its use?

Gepotidacin inhibits DNA gyrase and topoisomerase IV, enzymes bacteria need to replicate their genetic material. Its activity can persist against some organisms resistant to other antibiotic classes. However, bacteria can also develop reduced susceptibility to gepotidacin, so a different mechanism does not guarantee effectiveness. Culture and susceptibility results should inform treatment when available. [FDA prescribing information](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/218230s001lbl.pdf)

Diarrhea and nausea are common adverse reactions. The label also warns about QT prolongation, an electrical heart-rhythm change, and advises avoiding treatment in specified cardiac conditions, severe kidney or liver impairment, and with certain interacting medicines. These restrictions make medication review essential. The uncomplicated UTI evidence does not establish a treatment role for kidney infections or bloodstream infections. [FDA safety information and approved indications](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/218230s001lbl.pdf)